TKT Announces Executive Promotions
November 12 2004 - 8:15AM
PR Newswire (US)
TKT Announces Executive Promotions CAMBRIDGE, Mass., Nov. 12
/PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc.
(NASDAQ:TKTX) today announced that five key members of its
management team have been promoted. Neil Kirby, Ph.D. has been
promoted to Senior Vice President, Strategic Product Development
and named a section 16b officer of the company. The other
executives who received promotions include Paul (Kip) M. Martha,
M.D. to Senior Vice President and Chief Medical Officer, Gregory D.
Perry to Senior Vice President and Chief Financial Officer, Linda
H. Pettingell to Senior Vice President, Human Resources and
Corporate Services, and Suzanne L. Bruhn, Ph.D. to Vice President,
Global Regulatory Affairs. "These people form a key part of the
team that has done a tremendous job positioning the company for
future growth and I am very pleased to announce their promotions,"
said Michael J. Astrue, President and Chief Executive Officer of
TKT. Dr. Kirby joined TKT in January 2002 as Vice President,
Regulatory Affairs with over 18 years of industry and academic
experience, including an extensive background in global regulatory
affairs. At TKT he has managed global regulatory affairs and more
recently spearheaded the company's strategic planning initiative
and other portfolio management efforts. In this new role, Dr. Kirby
will have overall responsibility for TKT's program management,
regulatory affairs and strategic planning initiatives. He joined
TKT from Vertex Pharmaceuticals where he served as Program
Executive for its commercial and clinical HIV products. Prior to
joining Vertex, he served as Project Director, Hemophilia Products
at Genetics Institute where he managed all research and development
efforts associated with this product franchise. Dr. Kirby also held
a variety of regulatory appointments, including positions at both
Genetics Institute and Biogen. He received a B.Pharm and a Ph.D.
from the University of London. Dr. Martha joined TKT as Vice
President, Clinical Affairs in January 2004 where he has managed
all clinical research, biostatistics and clinical operations
activities related to the company's ongoing clinical development
programs. In his new role, he will have added responsibility for
TKT's medical affairs and pharmacovigilance functions and will
continue to have overall responsibility for the planning,
implementation and management of TKT's clinical development
programs. He joined TKT from Interleukin Genetics where he was
Chief Medical and Regulatory Officer and Vice President for
Clinical Research and Development. Prior to joining Interleukin,
Dr. Martha was Vice President, Clinical R&D at PRAECIS
Pharmaceuticals Inc. He also held several positions at Genentech,
including Director of Endocrinology and Neurology, where he had
overall responsibility for the clinical development of the
company's growth hormone products and related growth hormone factor
programs. Before joining the biotechnology industry, Dr. Martha was
an Assistant Professor at Tufts University School of Medicine and a
practicing Pediatric Endocrinologist at Baystate Medical Center. He
has authored or co- authored more than 100 articles, book chapters
and abstracts in the medical literature. He received a B.S. in
Biology from Trinity College and an M.D. from the University of
Connecticut School of Medicine. He received his professional
training in pediatrics and conducted his Internship/Residency at
the University of Connecticut School of Medicine and his Fellowship
in endocrinology at the University of Virginia Medical Center. Mr.
Perry joined TKT in May 2003 as Vice President, Finance and Chief
Financial Officer. Since joining the company he has expanded the
finance function, raised $94 million through the sale of
convertible debt, and assisted in the acquisition of TKT Europe.
Before joining TKT, he served as Senior Vice President, Finance and
Business Development, Life Sciences at PerkinElmer, Inc. In this
position, Mr. Perry was responsible for the financial management of
PerkinElmer's $500 million drug discovery tools and genetic disease
screening business, as well as information technology and business
development activities. Prior to joining PerkinElmer, he was Chief
Financial Officer of the Automotive Aftermarket Products Group at
Honeywell. During a fourteen-year tenure at General Electric, he
held numerous positions of increasing responsibility in finance and
business development, most recently as Chief Financial Officer of
GE Medical Systems, Europe. Mr. Perry received a B.A. in Economics
and Political Science from Amherst College. Ms. Pettingell joined
TKT as Vice President, Human Resources in September 2002 with
nearly 20 years of experience in the creation and execution of
numerous human resources practices and policies, including employee
development, rewards, benefits, and employment. Over the past two
years she has expanded the Human Resource function, including
initiatives in performance management, compensation, and
organizational development strategies. Before joining TKT, Ms.
Pettingell served as Vice President, Human Resources at Genetic
MicroSystems Inc. from 1998 through its acquisition by Affymetrix
Inc. in 2002. Ms. Pettingell was a founding partner at HR Alliance,
Inc. where she specialized in human resources for fast growth
biotechnology companies. She also held human resources positions at
KPMG, Inc. She received a B.S. in Business/Human Resource
Management from Northeastern University. Dr. Bruhn joined TKT in
1998 where she implemented the company's program management
function and processes, ultimately becoming Vice President, Program
Management. Dr. Bruhn became Vice President, Regulatory Affairs in
2003 and was responsible for all aspects of TKT's U.S. regulatory
affairs. Prior to joining TKT, she held a variety of positions at
CytoTherapeutics, Inc., including Program Manager for ophthalmic
indications and Scientist in the Department of Cell and Molecular
Neurobiology. Before joining the biotechnology industry, Dr. Bruhn
was a Post-Doctoral Research Fellow in the Department of Genetics
at Harvard Medical School. Dr. Bruhn received a B.S. from Iowa
State University of Science and Technology and a Ph.D. from
Massachusetts Institute of Technology. About TKT Transkaryotic
Therapies, Inc. is a biopharmaceutical company primarily focused on
researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the
company markets Replagal(TM), an enzyme replacement therapy for
Fabry disease, and is developing treatments for Hunter syndrome and
Gaucher disease. In addition to its focus on rare diseases, TKT
intends to commercialize Dynepo(TM), its Gene- Activated(R)
erythropoietin product for anemia related to kidney disease, in the
European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe,
Canada and South America. Additional information about TKT is
available on the company's website at http://www.tktx.com/. This
press release contains forward-looking statements regarding TKT's
management structure, as well as statements containing the words
"believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions. There are a number of important factors that could
cause the company's actual results to differ materially from those
indicated by such forward-looking statements, including whether TKT
will be able to successfully manage its operations including
financial operations, human resource management, regulatory
affairs, and other factors set forth under the caption "Risk
Factors" in the company's Quarterly Report on Form 10-Q filed
November 9, 2004, with the Securities and Exchange Commission and
are incorporated herein by reference. While the company may elect
to update forward-looking statements at some point in the future,
the company specifically disclaims any obligation to do so, even if
its expectations change. Gene-Activated(R) is a registered
trademark and Replagal(TM) is a trademark of Transkaryotic
Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis. For
More Information Contact: Justine E. Koenigsberg Senior Director,
Corporate Communications (617) 349-0271 Daniella M. Lutz Corporate
Communications Manager (617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications, +1-617-349-0271, or Daniella M. Lutz, Corporate
Communications Manager, +1-617-349-0205 both of Transkaryotic
Therapies, Inc. Web site: http://www.tktx.com/ Company News
On-Call: http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jul 2023 to Jul 2024